Investors

Date	Name	Title	Type	Shares Traded	Price Range
Dec 20, 2007	sanofi	Beneficial Owner (10% or more)	Statement of Ownership	0	n/a
Oct 13, 2010	sanofi	Beneficial Owner (10% or more)	Buy	1,017,401	28.00
Jun 2, 2010	baker charles a	Director	Option Execute	5,000	25.43
Jul 1, 2011	baker charles a	Director	Automatic Sell	11,000	55.94 - 57.40
Jul 1, 2011	baker charles a	Director	Option Execute	11,000	28.81
Aug 10, 2011	baker charles a	Director	Option Execute	4,000	28.81
Feb 15, 2008	baker charles a	Director	Automatic Sell	10,000	18.67 - 19.06
Feb 15, 2008	baker charles a	Director	Option Execute	10,000	7.91
Feb 20, 2009	baker charles a	Director	Automatic Sell	10,000	18.16
Feb 20, 2009	baker charles a	Director	Option Execute	10,000	7.66
Apr 17, 2012	baker charles a	Director	Automatic Sell	2,090	125.00
Apr 19, 2012	baker charles a	Director	Automatic Sell	12,910	125.00
Apr 17, 2012	baker charles a	Director	Option Execute	2,090	18.80
Apr 19, 2012	baker charles a	Director	Option Execute	12,910	18.80
Sep 5, 2012	baker charles a	Director	Automatic Sell	1,286	150.00
Sep 6, 2012	baker charles a	Director	Automatic Sell	13,714	150.00
Sep 5, 2012	baker charles a	Director	Option Execute	1,286	15.01
Sep 6, 2012	baker charles a	Director	Option Execute	13,714	15.01
Nov 26, 2012	baker charles a	Director	Automatic Sell	15,000	171.45 - 175.14
Nov 26, 2012	baker charles a	Director	Option Execute	15,000	9.17
Showing 1-20 of 633 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.